RBC Capital analyst Brian Abrahams maintained a Buy rating on Karyopharm Therapeutics (NASDAQ:KPTI) on Wednesday, setting a price target of $27, which is approximately 85.06% above the present share price of $14.59.
Abrahams expects Karyopharm Therapeutics to post earnings per share (EPS) of -$0.63 for the fourth quarter of 2020.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Karyopharm Therapeutics, with an average price target of $30.33.
The analysts price targets range from a high of $41 to a low of $20.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $33.51 million and a net profit of -$40.32 million. The company's market cap is $1.07 billion.
According to TipRanks.com, RBC Capital analyst Brian Abrahams is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 7.7% and a 48.41% success rate.
Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.